Clinical Trial AVX - 001
Clinical trial AVX-001 is the first study of PVX108 to be conducted in humans. The objectives of this trial are:
to determine the maximum dose that can be safely administered as a single injection
to assess the safety of repeat, escalating doses, administered once every 2 weeks.
Recruitment for clinical trial AVX-001 is now complete.
CMAX Clinical Research
Adelaide, South Australia.
Ph. 1800 150 433
Centre for Clinical Studies
Ph. 03 8593 9875
Are you interested in participating in future trials?
Please contact email@example.com